Thymosin Alpha-1 Workplace Considerations: What Patients Need to Know
HealthRX.com
No study measured thymosin alpha-1's effect on work
Key numbers
- 1.6 mgLabeled dose of Italian Zadaxin, given twice weekly for its authorized useSource: fda.gov, as cited Nov 7, 2026
- 1.8 to 2.6 hoursHalf-life after a subcutaneous dose in healthy volunteers, how long the drug stays in the bodySource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- risk ratio 0.72Serious adverse events versus comparison treatments in hepatitis B trials, below 1 means fewerSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- FDA status / Not approved in the US; four orphan drug designations are not an approval [1]
- Labeled schedule (Italy) / Zadaxin 1.6 mg subcutaneously or intramuscularly twice weekly, 4 weeks, then weeks 8 to 12 [1]
- Blood levels / Peak about 0.7 to 2 hours; half-life 1.8 to 2.6 hours; no accumulation over 5 daily doses [3][1]
- Committee vote / 4 yes, 17 no on December 4, 2024 [4]
- HHS peptide policy / Not among the six peptides in the October 2026 draft [5]
- WADA / Not named on the 2026 or 2027 Prohibited List [6]
Is thymosin alpha-1 approved anywhere?
A Drugs@FDA search found no US application for it [1]. A December 2024 FDA review notes four US orphan drug designations, which is a separate process from approval [1].
It is a medicine in some other countries. FDA lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. Two reviews by authors tied to the developer put the count at more than 30 countries in 2007 and over 35 in 2009 [7][8]. A 2014 company annual report claims approvals in parts of Asia-Pacific, Latin America, Eastern Europe and the Middle East, and FDA said it could not independently verify those broader claims [1].
What schedule is documented?
The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for four weeks from the first vaccination, repeated from week 8 to week 12 at the second [1]. The label says the product is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution with allergies, autoimmune disease and other immune-modulating drugs [1].
In healthy volunteers a subcutaneous dose peaks at about 0.7 to 2 hours, with a half-life of about 1.8 to 2.6 hours and no accumulation after five daily doses [3][1].
Which side effects could reach a workday?
FDA's search of its adverse-event database on April 22, 2024 found zero reports for thymosin alpha-1 [1]. Authors tied to the manufacturer report more than 4,400 trial participants and more than 17 million doses of Zadaxin after marketing, with adverse experiences described as infrequent and mild; that is company-linked data [1].
The 2026 Cochrane review of hepatitis B trials found thymosin alpha-1 may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1056 people; low-certainty evidence) and fewer non-serious ones (RR 0.47, 95% CI 0.27 to 0.83; very low certainty) [9]. It found little to no effect on quality of life [9].
What people on Reddit report
Accounts from r/cfs posts about whether people could keep working while using thymosin alpha-1. These are personal reports from people with fatigue conditions, not measured job outcomes.
being mild i was able to work part-time. now i cant work atm i am afraid of my future financial situation.Read the source discussion
I can now work full time, work outside in my garden planting and pulling weeds, take 30 minute walks, sing and dance along to music, be with people.Read the source discussion
Questions worth asking
Compounding and anti-doping
FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on December 4, 2024, on both the free base and the acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety [4]. On FDA's page of bulk substances that may raise significant safety risks, thymosin alpha-1 sits in the "nominated but withdrawn" table, having come off category 2 when the nominators withdrew; FDA's posted concerns remain [2]. It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [5].
It is not named on WADA's 2026 Prohibited List or the 2027 List [6]. WADA does name thymosin-beta-4 and TB-500, a different peptide, under growth factors [6].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is thymosin alpha-1 FDA-approved?
What dose is documented for thymosin alpha-1?
What did the 2026 Cochrane review find?
Is thymosin alpha-1 named on WADA's Prohibited List?
Is thymosin alpha-1 part of the HHS peptide enforcement policy?
References
Show all 11 referencesHide references
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.
- Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
- Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610.
- Reddit participants. be careful about thymosin alpha-1 (r/cfs). Accessed 2026-11-11.
- Reddit participants. I am now 75-80% of normal (r/cfs). Accessed 2026-11-11.